Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Terminated 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 16Lymphoid 10Myeloid 5Thoracic 4Gynecologic 4Gastrointestinal 4Plasma cell 3Breast 3Head & Neck 2Genitourinary 2Dermatologic 2Sarcoma 1Classical hematology 1CNS 1

Conditions

Multiple Myeloma 3Myelodysplastic Syndromes 2Lymphoma, Non-Hodgkin 2Leukemia, Myeloid, Acute 2Hodgkin Disease 2Hematologic Neoplasms 2Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Testicular Neoplasms 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Plasmacytoma 1Ovarian Neoplasms 1Osteosarcoma 1Neoplasms 1Melanoma 1Lymphoma 1Lung Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Leukemia 1Kidney Neoplasms 1Glioblastoma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Brain Neoplasms 1Bone Neoplasms 1

Interventions

Dexamethasone 870Lenalidomide 456Bortezomib 454Cyclophosphamide 365Melphalan 271Calcium Dobesilate 262daratumumab 233pomalidomide 207carfilzomib 182fludarabine phosphate 140fludarabine 136Thalidomide 125Peripheral Blood Stem Cell Transplantation 119Filgrastim 114ixazomib 93Mycophenolic Acid 90Granulocyte Colony-Stimulating Factor 89Whole-Body Irradiation 87Busulfan 87dexamethasone acetate 86Tacrolimus 78dexamethasone 21-phosphate 74Cyclosporine 68isatuximab 67auricularum 67Prednisone 65elotuzumab 58belantamab mafodotin 56Antilymphocyte Serum 56Etoposide 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × cc-486 × Plasma cell × Clear all
NCT04174196 2025-12-02

A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
21 enrolled
Plasma cell

Multiple Myeloma, Plasmacytoma

NCT02223052 2020-05-12

Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies

Celgene

Phase 1 Completed
89 enrolled
BreastCNSDermatologicGenitourinaryGynecologicHead & NeckLymphoidMyeloidOther hematologic neoplasmPlasma cellSarcomaThoracic

Urinary Bladder Neoplasms, Bone Neoplasms, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Glioblastoma, Hodgkin Disease, Kidney Neoplasms, Leukemia, Lung Neoplasms, Lymphoma, Lymphoma, Non-Hodgkin, Melanoma, Multiple Myeloma, Myelodysplastic Syndromes, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Osteosarcoma, Skin Neoplasms, Testicular Neoplasms, Thyroid Neoplasms, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Small Cell Lung Carcinoma

NCT01908387 2015-07-28

Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms

Celgene

Phase 1 Terminated
2 enrolled
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡